Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Subject-assessor Blind, Placebo Controlled Phase Ⅱ Study to Determine the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat

NCT03982225 is registered in ClinicalTrials.gov with AMIpharm Co., Ltd. as lead sponsor.

NCT NCT03982225
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03982225 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Subject-assessor Blind, Placebo Controlled Phase Ⅱ Study to Determine the Optimal Dose of AYP-101 S.C. Injection for the Reduction of Submental Fat
Lead sponsor
AMIpharm Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2019
Completion date
October 21, 2022
Enrollment
143 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

moderate or severe submental fullness